Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Research

| More

Biocon Limited - Slow recovery in biosimilars - ICICI Securities

Posted On: 2021-01-24 22:17:21 (Time Zone: Arizona, USA)


Biocon Limited (Biocon) reported lower than estimated Q3FY21 performance in biosimilars and generics segment. Consolidated revenues grew 7.8% to Rs18.5bn (I-Sec: Rs19.5bn), adjusted EBITDA margin was down 430bps to 21.6% (I-Sec: 25.4%) and adjusted PAT declined 16.9% to Rs1.7bn (I-Sec: Rs2.4bn). Lower margin is attributed to higher R&D expenses and employee costs. Delay in new launches and recovery in the environment would suppress margins in the near term but are expected to improve over medium term as the market normalises from impact of COVID-19. Dr Christiane Hamacher, has stepped down as the MD of Biocon Biologics and will be succeeded by Dr Arun Chandavarkar. Reiterate ADD with a revised target price of Rs443/share (earlier: Rs490/share).

- Research steady while generics and biosimilars disappoint: Research services grew 12.6% YoY with steady performance across its business segments. Company added a new project from 3DC that will support growth over medium term. Generics declined 2.6% YoY (-6.4% QoQ) to Rs5.6bn due to inventory correction of API products in the channel which were high in the distressed environment. Biosimilars segment grew 11.0% YoY during the quarter supported by steady market share in Ogiviri and Fulphila in the US and sales from the recently launched Semglee in US market. However, growth has been lower than expected as the company faced operational challenges due to lockdowns, delay in acquiring new tenders and reduced footfalls in hospital services and critical care due to the pandemic.

- Higher R&D and staff costs restrict margin: Company reported an improvement of 170bps in gross margin with improving business mix and higher contribution from biosimilar segment. However, staff and R&D expense jumped 23% and 31% respectively on a YoY basis. This sharp jump in costs is related to higher investment towards the biosimilars and generics pipeline and has hit EBITDA margin, which dropped 430bps YoY (-80bps QoQ) to 21.6%. PBT margins for biosimilars and generics segments declined to 14.4% and 9.6% respectively. Delay in recovery and new launches would suppress margins in the near term but are expected to improve over medium term as the market normalises from impact of COVID-19.

- Outlook: We expect revenue CAGR of 19.3% over FY20-FY23E resulting in EBITDA margin expansion of 450bps (with rising contribution from the high-margin biosimilars segment) and earnings CAGR of 34.2% over FY20E-FY23E. This would help generate healthy FCF of ~Rs11bn over FY21E-FY23E and improve return ratios.

- Valuation and risks: We reduce revenue and EBITDA estimates by 2-4% and 9-12% respectively over FY21E-FY23E to account for delay in new product launches and higher expenses towards R&D and personnel. Maintain ADD with a revised SoTP-based target price of Rs443/share (earlier: Rs490/share) Key downside risks: adverse regulation, delay in product launch, and higher competition in products.

Shares of BIOCON LTD. was last trading in BSE at Rs.393.8 as compared to the previous close of Rs. 441.95. The total number of shares traded during the day was 1386180 in over 39448 trades.

The stock hit an intraday high of Rs. 424 and intraday low of 386. The net turnover during the day was Rs. 556857995.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Easy Trip Planners Ltd. - IPO - Strong Financials - Reliance Securities

Bharat Forge - Initiating Coverage - Constant evolution - HDFC Securities

Mahindra Logistics - Large-ticket deal win - ICICI Securities

Company Update - Huhtamaki India - ICICI Direct

Gladiator Stocks: IndusInd Bank, VIP Industries - ICICI Direct

Warehousing demand expected to grow around 160% to reach 35 million sq. ft in 2021: JLL

Telecom - Spectrum auction: Prudent investment by Bharti Airtel - ICICI Securities

JB Chemicals & Pharmaceuticals - Analyst meet takeaways - ICICI Securities

IPO Review - MTAR Technologies Ltd - ICICI Direct

Auto Sector - Monthly Volume Round-up - Feb 21 - Decent YoY Growth Continues

Aditya Birla Fashion and Retail - Focus on scaling up new businesses - ICICI Securities

Automobiles (wholesale) - Wholesales push continues despite modest retail trends - ICICI Securities

Aditya Birla Capital - Thoughtful (inclusive) conglomerate business evolution commands premium - ICICI Securities

Jubilant Foodworks - Buying in-the-money options - ICICI Securities

Multi Commodity Exchange of India - Play on rising commodity prices? - ICICI Securities

Gladiator Stocks - Sudarshan Chemical - ICICI Direct

Monthly Commodities Outlook - March 2021 - ICICI Direct

ICICI Direct - Monthly Currency Outlook: Rupee to depreciate further towards 75.00 level...

ICICI Direct - Covid Recovery Pulse - E-way bill generation in February 2021 starts on strong note...

Company Update - Virtual JLR Investor Event - Tata Motors - ICICI Direct

Analyst Meet Update - Aditya Birla Fashion and Retail - ICICI Direct

MTAR Technologies Ltd. - IPO - Huge Opportunities from Clean Energy Bodes Well - Reliance Research

ICICI Direct Derivatives Weekly View (February 26): Failure to move above 14700 may extend declines towards 14300...

Bank: Sector Credit Trends - Slows, Yet again - HDFC Securities

Piramal Enterprises - Pharma day highlights - ICICI Securities

Polymer price tracker - PVC prices rise sharply again! - ICICI Securities

Greenply Industries - Growth returns, at an inflection point - ICICI Securities

Tata Motors - JLR future proofing itself with rapid electric transition - ICICI Securities

Dairy - Higher freight cost and increase in Global SMP prices - ICICI Securities

Analyst Meet Update - Nestlé India (Hold): Focus on product innovation, expanding rural reach - ICICI Direct

MTAR Technologies Ltd - A strong player in booming high precision engineering... - Geojit

Rollover Report for February - March 2021 : Angel Broking

Reaction from industry experts on Q3FY21 GDP numbers

M. Govinda Rao, Chief Economic Adviser, Brickwork ratings on Q3FY21 GDP numbers

Mr. Dhiraj Relli, MD & CEO, HDFC securities views on Q3FY21 GDP Growth Number

Suman Chowdhury, Chief Analytical Officer, Acuité Ratings & Research on Q3FY21 GDP

Rollover Analysis - Feb 21, 2021 - YES Securities

Consumer Durables - Demand-driven recovery continues - HDFC Securities

Cement - Demand surprises; earnings upgrade to continue - ICICI Securities

Gladiator Stocks - TeamLease Services - ICICI Direct

Gladiator Stocks - Metals to outshine post multi-year breakout... - ICICI Direct

Company Update - Sundaram Finance - ICICI Direct

Indian pharmaceutical industry to meet an ambition of US$130 billion by 2030 through innovation-led growth: EY-FICCI report

4th Industrial Conclave - Bullish undertone, favourable valuation - HDFC Securities

Sanofi India - Weak quarter; sequential improvement - ICICI Securities

Sunteck Realty - All eyes on upcoming launches - ICICI Securities

Company Update - Tata Motors - ICICI Direct

Q4CY20 Company Update - Mahindra CIE Automotive - ICICI Direct

Event Update - Hindalco - ICICI Direct

EY report launch at BioAsia 2021 - Moving the needle: Healthcare industry in a post-COVID world



Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020